Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of AML or ALL: CR2 or subsequent complete remission (CR) or CR1 with high-risk features or relapse with \< 10% blasts in BM and no circulating blasts.~2. Clinical diagnosis of CML: in CP1 (Chronic Phase 1) and resistant or intolerant to Gleevec or in CP2 or subsequent CP or in accelerated phase.~3. Clinical diagnosis of HD: induction failure or relapse and sensitive to last chemotherapy course.~4. Clinical diagnosis of NHL induction failure or relapse and sensitive to last chemotherapy course.~5. Clinical diagnosis of MDS with intermediate 2- or high-risk IPSS score.~Exclusion Criteria:~1. Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except Hydroxyurea).~2. HIV positive.~3. Pregnancy or lactation.~4. Uncontrolled bacterial, fungal or viral infection.~5. Subjects with signs and symptoms of active central nervous system (CNS) disease.~6. Availability of appropriate related and willing stem cell donor, who is HLA-matched at 5 or 6/6 antigens.~7. Prior allogeneic cell transplant.~8. Allergy to bovine or to any product, which may interfere with the treatment.~9. Enrolled in another clinical trial or received an investigational treatment during the last 30 days, unless approved by Sponsor.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- StemEx (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).